Un articulo en El País de uno de los asesores más próximos a Zapatero, Jose Andrés Torres Mora, demuestra claramente la política del enroque en la que se encuentra anclado el Ejecutivo: la movilización de los internautas es un asunto partidista, son gente a sueldo de otros partidos, o de las empresas de telecomunicaciones, o de algún oscuro contubernio judeomasónico, y el único problema es que o no han entendido el tema bien, o lo malinterpretan a propósito.

This publication provides an overview of the social movement for Drug Policy reform throughout Europe. The study presents drug-related factual information along with the perceptions of persons who use drugs (PWUD), and is based on a survey passed to relevant organizations and stakeholders.

Cellular model for arsenic testing DESCRIPTION OF THE INVENTION The invention “cellular model for arsenic testing” is based on the use of a new form of arsenic detection analysis, termed herein “Gold Test” (sometimes referred to herein as “GT”).

Cellular model for antiviral testing DESCRIPTION OF THE INVENTION The invention “cellular model for antiviral testing” is based on the use of a new form of virus detection analysis, termed herein “Gold Test” (sometimes referred to herein as “GT”).

DESCRIPTION OF THE INVENTION The invention “cellular model for antibiotic testing” is based on the use of a new form of microbial detection analysis, termed herein “Gold Test” (sometimes referred to herein as “GT”).

Formula matemática para el cálculo del número de personas en espacios cerrados con el objetivo de minimizar la transmisión del covid19

Cálculo del número de personas en lugares cerrados teniendo en cuenta una distancia de seguridad social de dos metros para minimizar los riesgos de propagación del coronavirus covid19

DESCRIPTION OF THE INVENTION The invention “Nucleic acid vaccine” is based on the use of a specific nucleic acid sequence. Vaccine inoculation providing for lung cancer model detection.

DESCRIPTION OF THE INVENTION The invention “Nucleic acid vaccine” is based on the use of a specific nucleic acid sequence. Vaccine inoculation providing for prostate cancer model detection.

DESCRIPTION OF THE INVENTION The invention “Nucleic acid vaccine” is based on the use of a specific nucleic acid sequence. Vaccine inoculation providing for breast cancer model detection.

Bussines Plan created by Dr. Luis CRUZ RODRIGUEZ (Date and place Birth: November 7th, 1978, Cienfuegos, Cuba) Project Named: A VACCINE CANDIDATE AGAINST THE NOVEL CORONAVIRUS (COVID-19) WITH EXOSOMES AS POTENTIAL BIOMARKERS OF VACCINATION

Dr. Luis CRUZ RODRIGUEZ developed a following work: A new coronavirus named Covid-19 was reported in Wuhan, China in December 2019. The first time these cases were published they were classified as “pneumonia of unknown etiology”. The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19. Different from both MERS-CoV and SARS-CoV, 2019-nCoV it is the seventh member of the family of coronaviruses to infect humans. We have designed a preventive vaccine in Silico aimed to protect against Covid-19 infection and transmission. Our analysis identified 16 microRNA (miRNA) with theorical Exosome Affinity (EA) with peptide among 85.44-92.84 range. According to antiviral monitoring after and before vaccination using the candidate miRNA-peptide number 13 (LCR_2020_B008-13) with value EA=92.84 Ro. We proposed the exosomes as biomarkers of SARS-Covid-2 in lung: after and before vaccination. Due to, the miRNA-peptides, in Silico, manifesting highly affinity with exosomes, where our chimera LCR_2020_B008-13 could reach a representative activity against the Covid-19 virogenes due to “exosome sequestering”; and also, the treatment of cancer diseases due to “podosome depletion” in metastasis stage

ABSTRACT: Human Immunodeficiency Virus (HIV) is an RNA retrovirus with great capacity for replication and mutation. It belongs to lentiviruses, which are characterized in that the interval between the initial infection and the beginning of the main symptoms is classified into two types: HIV-1 and HIV-2, which have 40-50% genetic homology and organization and similar genomics. HIV-1 is the cause of the global Acquired Immune Deficiency Syndrome (AIDS) pandemic while HIV-2, although it can also cause AIDS, is considered less pathogenic and less transmissible. Another differential characteristic of HIV-1 is its great genetic variability, which is contributing to making it difficult to understand the mechanisms by which the virus is capable of causing the acquired immune deficiency syndrome and which necessarily influences the development of diagnostic tests and its possibilities of prevention, the development of effective treatments and vaccines, or the appearance of resistance. We have designed a preventive vaccine in Silico aimed to protect against VIH-1 infection and transmission. One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors. Here, we present miRNA-peptide fusion more stable as an antiviral. Our analysis identified a miRNA-peptide with theoretical fusion value stability FS=80.75 Cruz, to treat HIV-1, named LCR_2020_B0119. The vaccine candidate presents in Silico an inhibiting action against HIV-1 and coronavirus (covid-19), making its use possible as a new double-action antiviral vaccine: anti-HIV-1 and anti-covid-19.

La Propiedad Intelectual del siguiente trabajo corresponde a Luis CRUZ RODRIGUEZ, nacido el 7 de noviembre de 1978 en Cienfuegos, Cuba, nacionalidad cubana. ABSTRACT A RNA-PEPTIDE FUSION AS A VACCINE CANDIDATE AGAINST THE NOBEL CORONAVIRUS (COVID-19) LAMBERT-BROWN D. (1) HOCHWIMMER B. (2), SELINUS O. (3), ZAYAS-TAMAYO AM. (4), CRUZ-RODRIGUEZ L. (,5,6,7) Author information: 1. CEO. Family Physician, FCMC&EXCELAB, Jamaica. 2. CEO. Hochwimmer B. & Asso. Pty Ltd, Albury, NSW, Australia. 3. Linneaus University, Linnegatan 2, Kalmar 39233, Sweden. 4. Excelab Co. Ltd., Microbiologist of Environmental Biotechnology Department., Jamaica. 5. 6.5. Excelab Co. Ltd., Manager Director of Environmental Biotechnology Department., Jamaica. 7.6. CEO. ELIDAN Dynamic LLC, 1602 Windermere Way, Tampa, FL,33619, USA. 8.7. CEO, ELIDAN genome SAS, 1 avenue du Lycée, 77130 Montereau Fault Yonne; France 9. emails: ceo@elidan-genome.com ; luis.cruzrguez@gmail.com ABSTRACT: A new coronavirus named COVID-19 was reported in Wuhan, China in December 2019. The COVID-19 epidemic is spreading rapidly all over the world, (Sun P. and col, 2020). Based on published data on COVID-19, we have designed a preventive vaccine in Silico aimed to protect against COVID-19 infection and transmission (Cascella M. and col, 2020). One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors (Wang Z., 2019). Here, we present to the miRNA-peptide fusion more stable as antiviral (Waterhouse A. and col 2018). As RNA target we used primers from Kemp V. “miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs”: primers Biolegio, Nijmegen, The Netherlands (Kemp V. and col, 2019). Our analysis identified a miRNA-peptide with theorical fusion value stability FS=64.28, to treat COVID-19, named LCR_2020_B008-1. Additionally, peptide LCR_2020_B008 can be used in solutions as disinfectant and antiviral, having a fast-hygienic utility to avoid contagion or the propagation of the Covid-19 disease. With respect to antiviral action, the candidate manifests LCR_2020_B008-1, in Silico, manifesting partial inhibiting activity on the VIH-1, and therefore readjustments on this chimera miRNA-peptide could reach a representative antiviral activity against the VIH-1.

Comentario de texto sobre la segunda carta de "Rights of man", de Thomas Paine, para la clase de Historia -EA0909-, en la Universidad Jaime I.

Portfolio del proyecto en el campo de refugiados de Moria, Lesbos. Día a día dentro del campo para el proyecto SOS Human.

Portfolio del proyecto en el campo de refugiados de Moria, Lesbos. Día a día dentro del campo para el proyecto SOS Human.

Portfolio del proyecto en el campo de refugiados de Moria, Lesbos. Día a día dentro del campo para el proyecto SOS Human.